Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. uri icon

authors

  • Weng, Yan
  • He, Tao
  • Logan, Alison
  • Lee, Darwin
  • Li, Dongmei
  • Zhou, Yingjiang
  • Bernardo, Barbara
  • Joyce, Alison
  • Kavosi, Mania
  • O'Hara, Denise M
  • Clark, Tracey
  • Ishino, Tetsuya
  • Giragossian, Craig
  • Stahl, Mark
  • Calle, Roberto A
  • Kriz, Ron
  • Somers, Will
  • Lin, Laura
  • Sievers, Annette
  • Talukdar, Saswata
  • Chabot, Jeffrey R
  • Tam, Amy
  • Duan, Weili
  • Kerns, Kelvin
  • Sousa, Eric

publication date

  • January 1, 2018